摘要
目的:探讨替诺福韦在乙型肝炎后肝硬化患者中的应用及对血清肿瘤相关抗原125(CA125)、甲胎蛋白(AFP)和癌胚抗原(CEA)水平的影响。方法:选取2016年7月—2017年7月我院收治的乙型肝炎后肝硬化患者102例,根据治疗方法不同分成两组,各51例。对照组给予拉米夫定(100 mg,qd)治疗,研究组给予富马酸替诺福韦二吡呋酯片(300 mg,qd)治疗,比较两组肝功能指标、血清学指标、治疗前后失代偿好转率、乙肝病毒基因(HBV DNA)转阴率以及乙型肝炎E抗原(HBeAg)转阴率。结果:治疗后两组天冬氨酸氨基转移酶(AST),丙氨酸氨基转移酶(ALT)、总胆红素(TBil)、Child—Pugh评分均优于治疗前,且研究组优于对照组,差异有统计学意义(P <0.05);研究组失代偿好转率、HBV DNA转阴率显著高于对照组,差异有统计学意义(P <0.05);治疗后研究组CA125、AFP和CEA低于对照组,差异有统计学意义(P <0.05)。结论:替诺福韦治疗乙型肝炎后肝硬化可有效改善患者肝功能,降低血清CA125、AFP和CEA水平,值得临床推广应用。
Objective:To investigate the application of tenofovir in patients with post-hepatitis B cirrhosis and its effect on serum tumor-associated antigen 125(CA125),alpha-fetoprotein(AFP)and carcinoembryonic antigen(CEA)levels.Methods:102 patients with post-hepatitis B cirrhosis admitted to our hospital from July 2016 to July 2017 were selected and divided into two groups according to different treatment methods,51 cases each.The patients in the control group were treated with lamivudine(100 mg,qd),and the patients in the study group were treated with tenofovir disoproxil fumarate tablets(300 mg,qd).The liver function indexes,serological indexes,decompensation improvement rate before and after treatment,the negative conversion rate of hepatitis B virus gene(HBV DNA)and the negative conversion rate of hepatitis B E antigen(HBeAg)were compared between the two groups.Results:The indexes of aspartate aminotransferase(AST),alanine aminotransferase(ALT)and total bilirubin(TBil)and the Child-Pugh scores in the two groups after treatment were better than those before treatment,and the indexes and the scores in the study group were better than those in the control group,with statistically significant differences(P<0.05).The decompensation improvement rate and the negative conversion rate of HBV DNA in the study group were significantly higher than those in the control group,with statistically significant differences(P<0.05).After treatment,the levels of CA125,AFP and CEA in the study group were lower than those in the control group,with statistically significant differences(P<0.05).Conclusion:Tenofovir can effectively improve liver functions and reduce serum CA125,AFP and CEA levels in treatment of post-hepatitis B cirrhosis,which is worthy of clinical application.
作者
肖兴国
吴慧丽
张磊
Xiao Xing-guo;Wu Hui-li;Zhang Lei(Department of Gastroenterology,Zhengzhou Central Hospital Affiliated to Zhengzhou University,Zhengzhou,Henan 450007,China)
出处
《中国合理用药探索》
CAS
2019年第2期89-92,共4页
Chinese Journal of Rational Drug Use
